Lulican® cream is made by reputable Glenmark, brand names Luzu, Lucoz cream. Lulican® contains luliconazole 1 percent, an azole antifungal agent, in a white cream for topical application. Lulican® Cream is used in the treatment of fungal infections, it works by preventing the synthesis of a substance in the fungal cell wall called peptidoglycan, which provides the cell wall with the strength required for survival of bacteria in the human body. Thus this then kills the cell and stops the infection from spreading.
HOW TO USE LULICAN LULICONAZOLE 1% CREAM
Lulican® with 1% luliconazole is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older. Tinea cruris: A superficial fungus infection of the crotch and perineum known popularly as jock itch. Good general hygiene helps prevent it, as does keeping the area clean and dry. Laundering underwear and athletic supporters frequently also help, as do an antifungal or drying powder after bathing. Lulican® is for topical use only.
When treating interdigital tinea pedis, a thin layer of Lulican® Cream 1% should be applied to the affected area and approximately 1 inch of the immediate surrounding area once daily for 2 weeks.
When treating tinea cruris or tinea corporis, Lulican® Cream 1% should be applied to the affected area and approximately 1 inch of the immediate surrounding area once daily for 1 week.
SIDE EFFECTS FROM LULICAN LULICONAZOLE 1% CREAM
Application site redness,
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 100 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2012). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers spread across India, UK, and Switzerland. It's subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India. Glenmark was founded with a vision to emerge as a leading integrated research-based, a global pharmaceutical company. Over the decades, we have established ourselves as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity). We have several molecules in various stages of pre-clinical and clinical development and are primarily focused in the areas of Oncology, Respiratory and Dermatology. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 80 countries including the US, various countries in the EU, South America and India. With 17 manufacturing facilities and 5 R&D centers dedicated to the goal of enriching lives across the globe we believe that the real force behind our continued successes are dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world'.